| Date | Title | Description |
| 08.07.2022 | All the good news dealmakers need this weekend | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Who’s tired of it? Doom and gloom. Doom and gloom. And—just for good measure—a little more doom a... |
| 08.07.2022 | Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction | Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value
Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners
CINCINNATI and SEOUL, South Korea, J... |
| 04.02.2022 | MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY | CINCINNATI, Feb. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021.
First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021... |
| 31.01.2022 | Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel | CINCINNATI, Jan. 31, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has been awarded additional funding in the... |
| 28.01.2022 | Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection | CINCINNATI, Jan. 28, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA... |
| 05.01.2022 | Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay | CINCINNATI, Jan. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food... |
| 02.12.2021 | Meridian Bioscience Announces Retirement of CFO Bryan Baldasare | CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chi... |
| 24.11.2021 | Meridian Bioscience Announces Retirement of Chairman David Phillips | CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Dire... |
| 17.11.2021 | Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing | CINCINNATI, Nov. 17, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its Air-Dryable™ LAMP Mix and Air-Dr... |
| 12.11.2021 | Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance | CINCINNATI, Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021.
Fourth Quarter 2021 Highlights (Comparison to Fourth Quart... |
| 10.11.2021 | Press Release dated November 10, 2021 - Form 8-K | For Immediate Release
Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene®SARS-CoV-2 Molecular Assay
CINCINNATI, November 10, 2021 (PRNewswire) - Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testi... |
| 10.11.2021 | Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay | CINCINNATI, Nov. 10, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use A... |
| 27.10.2021 | Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples | CINCINNATI, Oct. 27, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mix... |
| 07.10.2021 | Meridian Bioscience : Launches New Air-Dryable™ qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples | CINCINNATI, Oct. 7, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct RNA/DNA q... |
| 01.05.2020 | Meridian Bioscience Acquires Exalenz Bioscience | Meridian Bioscience, Inc. (NASDAQ: VIVO), a Cincinnati, OH-based provider of diagnostic testing solutions and life science raw materials, completed the acquisition of Exalenz Bioscience Ltd., a Modiin, Israel based provider of a urea breath... |
| 26.04.2012 | Meridian Bioscience in midst of clinical trials for two molecular tests | Cincinnati-area Meridian is betting big on the illumigene platform, which it says provides its hospital and laboratory customers with a simpler, cheaper option to test samples for certain types of bacteria without the use of expensive instr... |
| 21.03.2012 | Meridian Bioscience gets Australian OK for molecular group B strep test | Meridian received U.S. Food and Drug Administration clearance of the test in December.
Group B strep is a bacterial infection that can be passed to a woman’s baby during delivery. The bacteria is normally found in the vagina and/or rectum o... |
| 25.01.2012 | Meridian Bioscience: Molecular test for Mycoplasma now in clinical trials | After Mycoplasma, the next illumigene test Meridian is expected to release is for group A streptococcus, a type of bacteria often found on the throat or in the skin.
Cincinnati-area Meridian is betting big on the illumigene platform, which ... |
| 27.12.2011 | FDA approval rounds out Meridian Biosciences’ C. difficile test portfolio | This approval makes Meridian the only manufacturer that can provide a complete portfolio of C. difficile testing solutions, the company said in a press release. Meridian already has a few tests for C. difficile on the market, but sales stag... |
| 12.12.2011 | Meridian Bioscience gets FDA clearance for molecular group B strep test | The new group B strep (GBS) test yields results in an hour and works via a “simple” procedure that includes heat treatment, amplification and detection, according to a statement from Meridian.
GBS is a bacterial infection that can be passed... |
| 10.11.2011 | Meridian Bioscience to release up to four new illumigene tests in next year | Other new versions of the illumigene test include those for Mycoplasma pneumonia, an infection of the lungs; Group A streptococcus, a type of bacteria often found on the throat or in the skin; and Pertussis, a contagious bacterial disease t... |
| 18.03.2010 | Meridian rebounds slightly after cutting guidance | By Mary Vanac
Shares of Meridian Bioscience Inc. (NSDQ:VIVO) rebounded a bit Thursday — a day after the Cincinnati, Ohio-based diagnostics maker cut its sales and earnings outlook for the fiscal year ending in September, sending its shares ... |
| 25.02.2010 | Night Read (Ohio): Wright State University building $22M neuroscience center | Kent State University has named Mark A. James, professor and vice chair of the Department of Tropical Medicine at Tulane University School of Public Health and Tropical Medicine, as the founding dean of KSU’s College of Public Health, effec... |
| 01.02.2010 | MedCity News Q&A: Meridian Bioscience CEO Jack Kraeutler | By Mary Vanac
CINCINNATI, Ohio — Over the years, Meridian Bioscience Inc. has gotten good at making diagnostic test kits that detect bugs like C. difficile and H. pylori, both bacteria that can wreak havoc in the digestive tract — or worse.... |
| 29.01.2010 | Meridian Bioscience sees molecular tests as makeover of ‘just a little kit company’ image | Jack Kraeutler, chief executive of Meridian Bioscience, talked with MedCity News about the promise of this new generation of diagnostic tests — and potential acquisitions — for his company.
Q. In January, Meridian Bioscience started clini... |
| 21.01.2010 | Meridian Bioscience working on answer for C. difficile test competition: Illumigene | Illumigene is Meridian’s first molecular test kit that amplifies DNA in samples with technology licensed from Eiken Chemical Co. of Japan, the company said in its earnings statement.
In January, Meridian began clinical trials of its i... |
| 12.01.2010 | University of Cincinnati College of Medicine launches early stage cancer drug development program — MedCity Evening Read, Jan. 12, 2010 | The MetroHealth System in Cleveland has sold $75 million in Build America bonds (pdf) and will use the proceeds for capital projects throughout the system, according to Crain’s Cleveland.
You would think shares of Meridian Bioscience in Ci... |
| 17.09.2009 | Meridian Bioscience gets FDA clearance to add swine flu claims to rapid flu testing device | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 26.01.2009 | MedCity morning read, Monday, Jan. 26 | Meridian Bioscience makes diagnostic kits, and purified reagents and related products to enable the early diagnosis and treatment of common medical conditions, such as digestive and respiratory viruses. The company also makes technologies... |
| - | Meridian Bioscience gets FDA clearance to add swine flu claims to rapid flu testing device | CINCINNATI, Ohio — Meridian Bioscience Inc. has received clearance from the U.S. Food and Drug Administration to add two strains of 2009 H1N1 Influenza A virus — swine flu — to the sensitivity claims made by its TRU FLU flu testing dev... |
| - | University of Cincinnati College of Medicine launches early stage cancer drug development program — MedCity Evening Read, Jan. 12, 2010 | News and notes from a day in MedCity, Ohio:
The University of Cincinnati College of Medicine has launched an early stage cancer drug development program and phase-1 clinical trials unit for patients who have solid tumors that have resisted ... |
| - | Meridian Bioscience working on answer for C. difficile test competition: Illumigene | Â Updated 6:35 p.m.
CINCINNATI, Ohio — Meridian Bioscience Inc. reported record revenue and net income for its fiscal first quarter, despite increased competition for sales of C. difficile test kits.
The Cincinnati company that makes dia... |
| - | Meridian Bioscience: Molecular test for Mycoplasma now in clinical trials | Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs.
The illumigene Mycoplasma test is currently in clinical trials, according to... |
| - | Meridian Bioscience to release up to four new illumigene tests in next year | Meridian Bioscience (NASDAQ:VIVO) plans to launch up to four new tests from its illumigene molecular diagnostic testing platform over the next year.
Cincinnati-area Meridian is betting big on the illumigene platform, which it says provides ... |
| - | FDA approval rounds out Meridian Biosciences’ C. difficile test portfolio | Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test.
The ImmunoCard C. difficile GDH test has already been launched in global markets for scr... |
| - | Meridian Bioscience sees molecular tests as makeover of ‘just a little kit company’ image | CINCINNATI, Ohio — Over the years, Meridian Bioscience Inc. has gotten good at making diagnostic test kits that detect bugs like C. difficile and H. pylori, both bacteria that can wreak havoc in the digestive tract — or worse.
The longtime ... |
| - | MedCity morning read, Monday, Jan. 26 | CINCINNATI, Ohio — A slowing world economy is beginning to affect the sales growth of life sciences companies.
Last week, Meridian Bioscience Inc. in Cincinnati announced record net sales of $34.3 million for its first fiscal quarter, whic... |
| - | Meridian Bioscience gets Australian OK for molecular group B strep test | Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus.
The test is part of Cincinnati-area Meridian’s illumigene line of molecular diagnostic tests... |
| - | Meridian Bioscience in midst of clinical trials for two molecular tests | Meridian Bioscience‘s (NASDAQ:VIVO) has two molecular diagnostic tests in clinical trials, with another test expected to begin trials later in the year.
Currently in trials are tests built on the company’s illumigene molecular diagnostic te... |
| - | Meridian Bioscience gets FDA clearance for molecular group B strep test | Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus.
The group B strep test is the second in the Cincinnati-area company’s illumigene line of mo... |
| - | Night Read (Ohio): Wright State University building $22M neuroscience center | News and notes from the day in MedCity, Ohio:
Wright State University in Dayton plans to build a $22 million state-of-the-art center to make the university a national leader in neuroscience research, and Premier Health Partners plans to pro... |